Kimpel, Otilia
Bedrose, Sara http://orcid.org/0000-0003-1396-6384
Megerle, Felix
Berruti, Alfredo
Terzolo, Massimo
Kroiss, Matthias
Mai, Knut
Dekkers, Olaf M.
Habra, Mouhammed Amir
Fassnacht, Martin http://orcid.org/0000-0001-6170-6398
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (314061271, 641696, 314061271, 641697)
Article History
Received: 20 April 2021
Revised: 1 July 2021
Accepted: 22 July 2021
First Online: 16 August 2021
Ethics approval and consent to participate
: This cohort study was part of the ENSAT registry study (ExternalRef removed) in four European reference centres for ACC (Würzburg, Germany; Brescia, Italy; Berlin, Germany; and Orbassano, Italy) and the MD Anderson Cancer Center in Houston, US. It was approved by the ethics committees/institutional review boards at all participating institutions and all patients provided written informed consent. It was performed in accordance with the Declaration of Helsinki.
: Not applicable.
: MK received travel cost reimbursement, speaker honoraria, and research support from Ipsen Pharma. AB received funds for research in adrenocortical carcinoma from Novartis, Janssen Cilag and Sanofi. MT received speaker honoraria and research grants from HRA Pharma that were paid to the University Department. MAH received honoraria from HRA Pharma for the advisory board. MF has served in an advisory board of HRA Pharma on the management of adrenocortical carcinoma (2018 + 2021); remuneration was paid to his University Hospital. OK, SB, FM, KM and OMD declare no competing interests.